Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line

International Journal of Oncology

Volumn 40, Issue 5, 2012, Pages 1677-1682

  Barta, Pavel ^a   Malmberg, Jennie ^b   Melicharova, Ludmila ^a   Strandgård, John ^c   Orlova, Anna ^b   Tolmachev, Vladimir ^d   Laznicek, Milan ^a   Andersson, Karl ^c,d  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UPPSALA UNIVERSITY   (Sweden)

^c Ridgeview Instruments AB   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecules; Affinity; Cetuximab; Epidermal growth factor receptor; HER2; Trastuzumab

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; CELL LINE; DRUG BINDING; HOST CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY AFFINITY; HEP G2 CELLS; HUMANS; IODINE RADIOISOTOPES; KINETICS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; RADIOLIGAND ASSAY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS;

EID: 84860298947     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1307     Document Type: Article

References (19)

1. Chinn DC, Holland WS, Yoon JM, Zwerdling T and Mack PC: Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell-lines. Pediatr Blood Cancer: July 27, 2011 (Epub ahead of print).
2. Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M and Brechbiel MW: Cetuximab: Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 23: 619-631, 2008.
3. Björkelund H, Gedda L and Andersson K: Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context. PLoS One 6: e16536, 2011.
4. Nestor M: Effect of cetuximab treatment in squamous cell carcinomas. Tumor Biol 31: 141-147, 2010.
5. Xu FJ, Yu YH, Bae DS, Zhao XG, Slade SK, Boyer CM, Bast RC Jr and Zalutsky MR: Radioiodinated antibody targeting of the HER-2/neu oncoprotein. Nucl Med Biol 24: 451-459, 1997. (Pubitemid 27359624)
6. Andersson K, Björkelund H and Malmqvist M: Antibody-antigen interactions: What is the required time to equilibrium? Available from Nature Precedings , 2010.
7. Björke H and Andersson K: Automated, high-resolution cellular retention and uptake studies in vitro. Appl Radiat Isot 64: 901-905, 2006. (Pubitemid 43817538)
8. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005. (Pubitemid 40637826)
9. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001. (Pubitemid 33674041)
10. Marmor MD, Skaria KB and Yarden Y: Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58: 903-913, 2004. (Pubitemid 38221150)
11. Citri A and Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516, 2006. (Pubitemid 44036456)
12. 125I-EGF. PLoS One 6: e24739, 2011.
13. Press MF and Lenz HJ: EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 67: 2045-2075, 2007. (Pubitemid 47524565)
14. 131I-labelled human growth hormone of high specific radioactivity. Biochem J 89: 114-123, 1963.
15. 111In]-labeled CHX-A"DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines. Exp Ther Med 2: 523-528, 2011.
16. Andersson K and Malmqvist M: Method for the analysis of solid biological objects. Patent application WO 2,010,033,069, 2008.
17. Svitel J, Balbo A, Mariuzza RA, Gonzales NR and Schuck P: Combined affinity and rate constant distributions of ligand populations from experimental surface binding kinetics and equilibria. Biophys J 84: 4062-4077, 2003. (Pubitemid 36637898)
18. Barta P, Björkelund H and Andersson K: Circumventing the requirement of binding saturation for receptor quantification using interaction kinetic extrapolation. Nucl Med Commun 32: 863-867, 2011.
19. EGFR:2377 and cetuximab. Int J Oncol 38: 1137-1143, 2011.